查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1617062

到 2030 年抗神經絲 L 抗體的全球市場預測：按產品類型、應用、最終用戶和地區進行分析

Anti Neurofilament L Antibody Market Forecasts to 2030 - Global Analysis By Product Type (Monoclonal Antibodies, Polyclonal Antibodies and Other Product Types), Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2024 年全球抗神經絲 L 抗體市場規模為 3.188 億美元，預計到 2030 年將達到 6.1258 億美元，預測期內複合年成長率為 11.5%。

抗神經絲 L (NfL) 抗體是專門設計用於與神經絲輕鏈 (NfL) 結合的特殊蛋白質，神經絲輕鍊是神經細胞中普遍存在的結構蛋白。 NfL是識別神經元損傷的重要生物標記物，可用於研究和診斷日益增多的阿茲海默症、多發性硬化症和肌萎縮側索硬化症（ALS）等神經退化性疾病。這些抗體支持神經系統疾病的早期檢測和監測，對於開發診斷分析、研究神經元完整性和推進治療技術至關重要。

據帕金森氏症基金會稱，截至 2022 年，美國約有 100 萬人患有帕金森氏症 (PD)。

神經退化性疾病盛行率上升

對抗神經絲 L (NfL) 抗體的需求主要是由神經退化性疾病（如多發性硬化症、帕金森氏症和阿茲海默症）日益流行所驅動。 NfL 是識別神經元細胞損傷的重要生物標記物，可用於早期診斷和病情監測。隨著全球人口老化和這些疾病盛行率的增加，越來越需要先進的診斷技術。此外，學術界和醫療保健專業人員對 NfL 生物標記重要性的廣泛了解加速了其在臨床和研究環境中的使用，支持了市場擴張。

缺乏標準化的檢測法

缺乏標準化檢測方法是抗神經絲 L (NfL) 抗體市場的主要挑戰，這對市場成長產生負面影響。檢測通訊協定的變異性會損害臨床診斷和研究的可靠性和再現性。這削弱了研究人員、醫生和監管機構的信心，並阻礙了更廣泛的採用。此外，缺乏通用標準使得很難比較不同研究的資料，從而減緩了新治療方法的開發和神經退化性疾病的研究。為了解決這個問題，相關人員必須共同努力製定規範，以確保準確性、統一性和更廣泛的可用性。

生物標記研究進展

生物標記研究正在推動抗神經絲 L (NfL) 抗體市場的顯著成長。自從 NfL 被確定為神經退化性疾病的重要生物標記以來，超靈敏免疫測量（例如 Simoa）等新技術已將檢測能力提高到以前無法達到的水平。這些進展使得早期診斷多發性硬化症、阿茲海默症和 ALS 等疾病、追蹤病程、評估治療效果等變得更加容易。隨著研究進展證明 NfL 在臨床試驗中的效用，製藥公司現在正在投資生物標記研究。

假陽性和假陰性的可能性

儘管 NfL 是神經退化性疾病的一種有前途的生物標記物，但它也存在假陽性和假陰性結果的風險，這可能會顯著影響臨床決策。樣品處理、儲存條件和干擾物質的存在等因素可能會影響 NfL 測量的準確性。此外，個體 NfL 水平各不相同，因此很難建立明確的診斷閾值。最佳化檢測通訊協定、使用高品質試劑並實施嚴格的品管措施對於最大限度地減少錯誤結果的風險至關重要。

COVID-19 的影響

抗神經絲 L (NfL) 抗體的銷售受到 COVID-19 疫情的嚴重影響。由於 COVID-19 與神經發炎和神經退化等神經系統症狀有關，因此人們越來越關注 NfL 作為確定神經損傷程度和追蹤疾病進程的生物標記。因此，出於診斷和研究目的，對 NfL 抗體的需求不斷增加。基於 NfL 的診斷測試的採用也可能受到以下事實的影響：大流行加速了遠距醫療解決方案的開發。

單株抗體領域預計將成為預測期內最大的市場

單株抗體片段估計是最大的，因為它們的高特異性、敏感性和重現性使其成為檢測和定量各種生物樣本中 NfL 水平的理想選擇。單株抗體可設計用於靶向 NfL 蛋白上的特定表位，從而實現精確且準確的測量。此外，單株抗體技術的進步促進了高靈敏度和特異性檢測的發展，進一步推動了市場成長。

學術機構領域預計在預測期內複合年成長率最高

學術機構領域預計在預測期內複合年成長率最高。這些機構對神經退化性疾病進行廣泛的研究，利用 NfL 作為有價值的生物標記來了解疾病機制並確定潛在的治療標靶。用於研究目的的高品質 NfL 抗體的需求正在推動市場成長。此外，與製藥和生物技術公司的學術合作正在加速基於 NfL 的創新診斷工具和治療性介入的開發。

比最大的地區

由於人口迅速老化、神經系統疾病發病率上升以及醫療設施擴張，預計亞太地區將在預測期內佔據最大的市場佔有率。該地區龐大的人口和不斷成長的醫療保健支出顯著增加了對 NfL 檢測等先進診斷設備的需求。政府支持醫療保健和醫學研究的計劃的增加也推動了市場擴張。隨著該地區進一步開發市場，對 NfL 抗體的需求預計將會增加，使其成為國際公司的重要市場。

複合年成長率最高的地區：

由於其發達的醫療基礎設施、不斷增加的老年人口以及對醫療保健研究和開發的重視，預計北美在預測期內的複合年成長率最高。該地區 ALS 和老年失智症神經退化性疾病的發生率不斷增加，增加了對 NfL 等精確、敏感生物標記的需求。此外，北美著名製藥和生物技術公司的存在也促進了基於 NfL 的診斷測試和治療性介入的開發和行銷。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭標基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球抗神經絲 L 抗體市場：依產品類型

  • 單株抗體
  • 多株抗體
  • 其他產品類型

第6章全球抗神經絲 L 抗體市場：依應用分類

  • 研究
  • 診斷
  • 藥物發現與開發
  • 治療藥物
  • 其他用途

第7章全球抗神經絲 L 抗體市場：依最終用戶分類

  • 學術機構
  • 製藥和生物技術公司
  • 研究所
  • 其他最終用戶

第8章全球抗神經絲L抗體市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第9章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第 10 章 公司概況

  • Merck KGaA
  • Abcam plc
  • Thermo Fisher Scientific Inc.
  • Santa Cruz Biotechnology, Inc.
  • Proteintech Group, Inc.
  • R&D Systems, Inc.
  • Boster Biological Technology
  • Rockland Immunochemicals Inc.
  • Bio-Rad Laboratories, Inc.
  • Cell Signaling Technology, Inc.
  • GeneTex, Inc.
  • Novus Biologicals, LLC
  • ProSci Inc.
  • Atlas Antibodies AB
  • LifeSpan BioSciences, Inc.
  • Creative Biolabs
  • BioLegend, Inc.
  • Abnova Corporation
  • PeproTech, Inc.
  • US Biological Life Sciences
Product Code: SMRC27939

According to Stratistics MRC, the Global Anti Neurofilament L Antibody Market is accounted for $318.80 million in 2024 and is expected to reach $612.58 million by 2030 growing at a CAGR of 11.5% during the forecast period. Anti-neurofilament L (NfL) antibodies are specialized proteins made to attach to the neurofilament light chain (NfL), a structural protein that is widely present in neurons. Research and diagnosis of neurodegenerative illnesses like Alzheimer's, multiple sclerosis, and amyotrophic lateral sclerosis (ALS) are increasingly using NfL, a critical biomarker for identifying neuronal damage. These antibodies support early detection and monitoring of neurological diseases and are essential for the development of diagnostic assays, research into neuronal integrity, and advancement of therapeutic techniques.

According to Parkinson's Foundation, as of 2022, nearly one million people in the United States are living with Parkinson's disease (PD).

Market Dynamics:

Driver:

Rising prevalence of neurodegenerative diseases

The need for anti-neurofilament L (NfL) antibodies is mostly driven by the increasing incidence of neurodegenerative illnesses such as multiple sclerosis, Parkinson's, and Alzheimer's. NfL is an essential biomarker for identifying neuronal injury, which helps with early diagnosis and status monitoring. Advanced diagnosis technologies are becoming more and more necessary as populations age and the prevalence of these ailments rises worldwide. Furthermore, increased knowledge of the significance of NfL biomarkers among academics and healthcare professionals has accelerated their use in clinical and research settings, supporting the market's expansion.

Restraint:

Lack of standardized assay methods

The lack of standardized assay methods in the Anti-Neurofilament L (NfL) Antibody Market poses significant challenges, negatively impacting its growth. Assay protocol variability produces variable results, which compromises clinical diagnostics and research study reliability and reproducibility. This hinders wider adoption by undermining trust among academics, physicians, and regulatory agencies. Furthermore, the lack of common standards makes it more difficult to compare data from different studies, which slows down the development of new treatments and research on neurodegenerative diseases. In order to resolve this issue, stakeholders must work together to create norms that guarantee accuracy, uniformity, and wider accessibility.

Opportunity:

Advancements in biomarker research

Research on biomarkers is propelling the market for anti-neurofilament L (NfL) antibodies to rise significantly. Novel technologies such as ultrasensitive immunoassays (e.g., Simoa) have improved detection capabilities at previously unachievable levels since NfL was identified as a crucial biomarker for neurodegenerative disorders. These developments facilitate early diagnosis, tracking the course of the disease, and assessing the effectiveness of treatment, especially for diseases like multiple sclerosis, Alzheimer's, and ALS. Pharmaceutical corporations are now investing in biomarker studies as a result of research advances that have demonstrated the usefulness of NfL in clinical trials.

Threat:

Potential for false positive and negative results

While NfL is a promising biomarker for neurodegenerative diseases, there is a risk of false positive and negative results, which can significantly impact clinical decision-making. Factors such as sample handling, storage conditions, and the presence of interfering substances can influence the accuracy of NfL measurements. Additionally, variations in individual NfL levels can make it challenging to establish definitive diagnostic thresholds. To minimize the risk of false results, it is essential to optimize assay protocols, use high-quality reagents, and implement rigorous quality control measures.

Covid-19 Impact

Anti-Neurofilament L (NfL) antibody sales have been greatly influenced by the COVID-19 epidemic. Since COVID-19 has been linked to neurological symptoms like neuroinflammation and neurodegeneration, there has been more interest in NfL as a possible biomarker for determining the extent of neurological damage and tracking the course of the illness. As a result, there is now more demand for NfL antibodies for both diagnostic and research applications. The adoption of NfL-based diagnostic tests may also be influenced by the pandemic's acceleration of the development of remote healthcare solutions.

The monoclonal antibodies segment is expected to be the largest during the forecast period

The monoclonal antibodies segment is estimated to be the largest, due to their high specificity, sensitivity, and reproducibility make them ideal for detecting and quantifying NfL levels in various biological samples. Monoclonal antibodies can be engineered to target specific epitopes on the NfL protein, enabling precise and accurate measurements. Additionally, advances in monoclonal antibody technology have led to the development of highly sensitive and specific assays, further driving the growth of the market.

The academic institutions segment is expected to have the highest CAGR during the forecast period

The academic institutions segment is anticipated to witness the highest CAGR during the forecast period. These institutions conduct extensive research on neurodegenerative diseases, utilizing NfL as a valuable biomarker to understand disease mechanisms and identify potential therapeutic targets. The demand for high-quality NfL antibodies for research purposes fuels the market's growth. Additionally, academic collaborations with pharmaceutical companies and biotechnology firms accelerate the development of innovative NfL-based diagnostic tools and therapeutic interventions.

Region with largest share:

Asia Pacific is expected to have the largest market share during the forecast period due to rapidly aging population, rising neurological disease rates, and expanding medical facilities. The need for sophisticated diagnostic instruments like NfL tests has increased significantly because to the region's high population and growing healthcare expenditures. The market's expansion is also being driven by an increase in government programs to support healthcare and medical research. The demand for NfL antibodies is anticipated to increase as the region develops further, making it a crucial market for international companies.

Region with highest CAGR:

North America is projected to witness the highest CAGR over the forecast period, because of a developed healthcare infrastructure, a growing senior population, and a strong emphasis on healthcare research and development. The increasing incidence of neurodegenerative illnesses like ALS and Alzheimer's in the area has raised the need for precise and sensitive biomarkers like NfL. Furthermore, the development and marketing of NfL-based diagnostic tests and therapeutic interventions have been expedited by the presence of prominent pharmaceutical and biotechnology firms in North America.

Key players in the market

Some of the key players profiled in the Anti Neurofilament L Antibody Market include Merck KGaA, Abcam plc, Thermo Fisher Scientific Inc., Santa Cruz Biotechnology, Inc., Proteintech Group, Inc., R&D Systems, Inc., Boster Biological Technology, Rockland Immunochemicals Inc., Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., GeneTex, Inc., Novus Biologicals, LLC, ProSci Inc., Atlas Antibodies AB, LifeSpan BioSciences, Inc., Creative Biolabs, BioLegend, Inc., Abnova Corporation, PeproTech, Inc., and US Biological Life Sciences.

Key Developments:

In October 2023, Quanterix Corporation launched a new high-sensitivity assay for measuring neurofilament light chain (NfL) levels, aimed at enhancing the early detection and monitoring of neurodegenerative diseases.

In September 2023, BioLegend introduced a new anti-neurofilament L antibody aimed at research applications, providing enhanced specificity and sensitivity for studying neurodegeneration.

In April 2023, Merck KGaA released an updated version of their anti-neurofilament L antibody, which includes improved formulations for better performance in clinical diagnostics.

Product Types Covered:

  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Other Product Types

Applications Covered:

  • Research
  • Diagnostics
  • Drug Discovery and Development
  • Therapeutics
  • Other Applications

End Users Covered:

  • Academic Institutions
  • Pharmaceutical and Biotechnology Companies
  • Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Anti Neurofilament L Antibody Market, By Product Type

  • 5.1 Introduction
  • 5.2 Monoclonal Antibodies
  • 5.3 Polyclonal Antibodies
  • 5.4 Other Product Types

6 Global Anti Neurofilament L Antibody Market, By Application

  • 6.1 Introduction
  • 6.2 Research
  • 6.3 Diagnostics
  • 6.4 Drug Discovery and Development
  • 6.5 Therapeutics
  • 6.6 Other Applications

7 Global Anti Neurofilament L Antibody Market, By End User

  • 7.1 Introduction
  • 7.2 Academic Institutions
  • 7.3 Pharmaceutical and Biotechnology Companies
  • 7.4 Laboratories
  • 7.5 Other End Users

8 Global Anti Neurofilament L Antibody Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Merck KGaA
  • 10.2 Abcam plc
  • 10.3 Thermo Fisher Scientific Inc.
  • 10.4 Santa Cruz Biotechnology, Inc.
  • 10.5 Proteintech Group, Inc.
  • 10.6 R&D Systems, Inc.
  • 10.7 Boster Biological Technology
  • 10.8 Rockland Immunochemicals Inc.
  • 10.9 Bio-Rad Laboratories, Inc.
  • 10.10 Cell Signaling Technology, Inc.
  • 10.11 GeneTex, Inc.
  • 10.12 Novus Biologicals, LLC
  • 10.13 ProSci Inc.
  • 10.14 Atlas Antibodies AB
  • 10.15 LifeSpan BioSciences, Inc.
  • 10.16 Creative Biolabs
  • 10.17 BioLegend, Inc.
  • 10.18 Abnova Corporation
  • 10.19 PeproTech, Inc.
  • 10.20 US Biological Life Sciences

List of Tables

  • Table 1 Global Anti Neurofilament L Antibody Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Anti Neurofilament L Antibody Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 3 Global Anti Neurofilament L Antibody Market Outlook, By Monoclonal Antibodies (2022-2030) ($MN)
  • Table 4 Global Anti Neurofilament L Antibody Market Outlook, By Polyclonal Antibodies (2022-2030) ($MN)
  • Table 5 Global Anti Neurofilament L Antibody Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 6 Global Anti Neurofilament L Antibody Market Outlook, By Application (2022-2030) ($MN)
  • Table 7 Global Anti Neurofilament L Antibody Market Outlook, By Research (2022-2030) ($MN)
  • Table 8 Global Anti Neurofilament L Antibody Market Outlook, By Diagnostics (2022-2030) ($MN)
  • Table 9 Global Anti Neurofilament L Antibody Market Outlook, By Drug Discovery and Development (2022-2030) ($MN)
  • Table 10 Global Anti Neurofilament L Antibody Market Outlook, By Therapeutics (2022-2030) ($MN)
  • Table 11 Global Anti Neurofilament L Antibody Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 12 Global Anti Neurofilament L Antibody Market Outlook, By End User (2022-2030) ($MN)
  • Table 13 Global Anti Neurofilament L Antibody Market Outlook, By Academic Institutions (2022-2030) ($MN)
  • Table 14 Global Anti Neurofilament L Antibody Market Outlook, By Pharmaceutical and Biotechnology Companies (2022-2030) ($MN)
  • Table 15 Global Anti Neurofilament L Antibody Market Outlook, By Laboratories (2022-2030) ($MN)
  • Table 16 Global Anti Neurofilament L Antibody Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 17 North America Anti Neurofilament L Antibody Market Outlook, By Country (2022-2030) ($MN)
  • Table 18 North America Anti Neurofilament L Antibody Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 19 North America Anti Neurofilament L Antibody Market Outlook, By Monoclonal Antibodies (2022-2030) ($MN)
  • Table 20 North America Anti Neurofilament L Antibody Market Outlook, By Polyclonal Antibodies (2022-2030) ($MN)
  • Table 21 North America Anti Neurofilament L Antibody Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 22 North America Anti Neurofilament L Antibody Market Outlook, By Application (2022-2030) ($MN)
  • Table 23 North America Anti Neurofilament L Antibody Market Outlook, By Research (2022-2030) ($MN)
  • Table 24 North America Anti Neurofilament L Antibody Market Outlook, By Diagnostics (2022-2030) ($MN)
  • Table 25 North America Anti Neurofilament L Antibody Market Outlook, By Drug Discovery and Development (2022-2030) ($MN)
  • Table 26 North America Anti Neurofilament L Antibody Market Outlook, By Therapeutics (2022-2030) ($MN)
  • Table 27 North America Anti Neurofilament L Antibody Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 28 North America Anti Neurofilament L Antibody Market Outlook, By End User (2022-2030) ($MN)
  • Table 29 North America Anti Neurofilament L Antibody Market Outlook, By Academic Institutions (2022-2030) ($MN)
  • Table 30 North America Anti Neurofilament L Antibody Market Outlook, By Pharmaceutical and Biotechnology Companies (2022-2030) ($MN)
  • Table 31 North America Anti Neurofilament L Antibody Market Outlook, By Laboratories (2022-2030) ($MN)
  • Table 32 North America Anti Neurofilament L Antibody Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 33 Europe Anti Neurofilament L Antibody Market Outlook, By Country (2022-2030) ($MN)
  • Table 34 Europe Anti Neurofilament L Antibody Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 35 Europe Anti Neurofilament L Antibody Market Outlook, By Monoclonal Antibodies (2022-2030) ($MN)
  • Table 36 Europe Anti Neurofilament L Antibody Market Outlook, By Polyclonal Antibodies (2022-2030) ($MN)
  • Table 37 Europe Anti Neurofilament L Antibody Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 38 Europe Anti Neurofilament L Antibody Market Outlook, By Application (2022-2030) ($MN)
  • Table 39 Europe Anti Neurofilament L Antibody Market Outlook, By Research (2022-2030) ($MN)
  • Table 40 Europe Anti Neurofilament L Antibody Market Outlook, By Diagnostics (2022-2030) ($MN)
  • Table 41 Europe Anti Neurofilament L Antibody Market Outlook, By Drug Discovery and Development (2022-2030) ($MN)
  • Table 42 Europe Anti Neurofilament L Antibody Market Outlook, By Therapeutics (2022-2030) ($MN)
  • Table 43 Europe Anti Neurofilament L Antibody Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 44 Europe Anti Neurofilament L Antibody Market Outlook, By End User (2022-2030) ($MN)
  • Table 45 Europe Anti Neurofilament L Antibody Market Outlook, By Academic Institutions (2022-2030) ($MN)
  • Table 46 Europe Anti Neurofilament L Antibody Market Outlook, By Pharmaceutical and Biotechnology Companies (2022-2030) ($MN)
  • Table 47 Europe Anti Neurofilament L Antibody Market Outlook, By Laboratories (2022-2030) ($MN)
  • Table 48 Europe Anti Neurofilament L Antibody Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 49 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Country (2022-2030) ($MN)
  • Table 50 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 51 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Monoclonal Antibodies (2022-2030) ($MN)
  • Table 52 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Polyclonal Antibodies (2022-2030) ($MN)
  • Table 53 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 54 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Application (2022-2030) ($MN)
  • Table 55 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Research (2022-2030) ($MN)
  • Table 56 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Diagnostics (2022-2030) ($MN)
  • Table 57 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Drug Discovery and Development (2022-2030) ($MN)
  • Table 58 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Therapeutics (2022-2030) ($MN)
  • Table 59 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 60 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By End User (2022-2030) ($MN)
  • Table 61 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Academic Institutions (2022-2030) ($MN)
  • Table 62 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Pharmaceutical and Biotechnology Companies (2022-2030) ($MN)
  • Table 63 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Laboratories (2022-2030) ($MN)
  • Table 64 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 65 South America Anti Neurofilament L Antibody Market Outlook, By Country (2022-2030) ($MN)
  • Table 66 South America Anti Neurofilament L Antibody Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 67 South America Anti Neurofilament L Antibody Market Outlook, By Monoclonal Antibodies (2022-2030) ($MN)
  • Table 68 South America Anti Neurofilament L Antibody Market Outlook, By Polyclonal Antibodies (2022-2030) ($MN)
  • Table 69 South America Anti Neurofilament L Antibody Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 70 South America Anti Neurofilament L Antibody Market Outlook, By Application (2022-2030) ($MN)
  • Table 71 South America Anti Neurofilament L Antibody Market Outlook, By Research (2022-2030) ($MN)
  • Table 72 South America Anti Neurofilament L Antibody Market Outlook, By Diagnostics (2022-2030) ($MN)
  • Table 73 South America Anti Neurofilament L Antibody Market Outlook, By Drug Discovery and Development (2022-2030) ($MN)
  • Table 74 South America Anti Neurofilament L Antibody Market Outlook, By Therapeutics (2022-2030) ($MN)
  • Table 75 South America Anti Neurofilament L Antibody Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 76 South America Anti Neurofilament L Antibody Market Outlook, By End User (2022-2030) ($MN)
  • Table 77 South America Anti Neurofilament L Antibody Market Outlook, By Academic Institutions (2022-2030) ($MN)
  • Table 78 South America Anti Neurofilament L Antibody Market Outlook, By Pharmaceutical and Biotechnology Companies (2022-2030) ($MN)
  • Table 79 South America Anti Neurofilament L Antibody Market Outlook, By Laboratories (2022-2030) ($MN)
  • Table 80 South America Anti Neurofilament L Antibody Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 81 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Country (2022-2030) ($MN)
  • Table 82 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 83 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Monoclonal Antibodies (2022-2030) ($MN)
  • Table 84 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Polyclonal Antibodies (2022-2030) ($MN)
  • Table 85 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 86 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Application (2022-2030) ($MN)
  • Table 87 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Research (2022-2030) ($MN)
  • Table 88 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Diagnostics (2022-2030) ($MN)
  • Table 89 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Drug Discovery and Development (2022-2030) ($MN)
  • Table 90 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Therapeutics (2022-2030) ($MN)
  • Table 91 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 92 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By End User (2022-2030) ($MN)
  • Table 93 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Academic Institutions (2022-2030) ($MN)
  • Table 94 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Pharmaceutical and Biotechnology Companies (2022-2030) ($MN)
  • Table 95 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Laboratories (2022-2030) ($MN)
  • Table 96 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Other End Users (2022-2030) ($MN)